194 related articles for article (PubMed ID: 8541129)
1. Clinical significance of serum S100 in metastatic malignant melanoma.
Guo HB; Stoffel-Wagner B; Bierwirth T; Mezger J; Klingmüller D
Eur J Cancer; 1995 Oct; 31A(11):1898-902. PubMed ID: 8541129
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of serum S100 in metastatic malignant melanoma.
Guo HB; Stoffel-Wagner B; Bierwirth T; Mezger J; Klingmüller D
Eur J Cancer; 1995 Jun; 31A(6):924-8. PubMed ID: 7646923
[TBL] [Abstract][Full Text] [Related]
3. S-100 and NSE as serum markers in melanoma.
Tofani A; Cioffi RP; Sciuto R; Rea S; Festa A; Di Filippo F; Cavaliere R; Maini CL
Acta Oncol; 1997; 36(7):761-4. PubMed ID: 9490097
[TBL] [Abstract][Full Text] [Related]
4. Serum S100--a marker for disease monitoring in metastatic melanoma.
Henze G; Dummer R; Joller-Jemelka HI; Böni R; Burg G
Dermatology; 1997; 194(3):208-12. PubMed ID: 9187834
[TBL] [Abstract][Full Text] [Related]
5. S100 protein serum levels in cutaneous malignant melanoma.
Seregni E; Massaron S; Martinetti A; Illeni MT; Rovini D; Belli F; Agresti R; Greco M; Cascinelli N; Bombardieri E
Oncol Rep; 1998; 5(3):601-4. PubMed ID: 9538159
[TBL] [Abstract][Full Text] [Related]
6. Melanoma progression and serum L-dopa/L-tyrosine ratio: a comparison with S100B.
Stoitchkov K; Letellier S; Garnier JP; Bousquet B; Tsankov N; Morel P; Ghanem G; Le Bricon T
Melanoma Res; 2002 Jun; 12(3):255-62. PubMed ID: 12140382
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two prognostic markers for malignant melanoma: MIA and S100 beta.
Juergensen A; Holzapfel U; Hein R; Stolz W; Buettner R; Bosserhoff A
Tumour Biol; 2001; 22(1):54-8. PubMed ID: 11054027
[TBL] [Abstract][Full Text] [Related]
8. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma.
Jury CS; McAllister EJ; MacKie RM
Br J Dermatol; 2000 Aug; 143(2):269-74. PubMed ID: 10951132
[TBL] [Abstract][Full Text] [Related]
9. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma.
Schultz ES; Diepgen TL; Von Den Driesch P
Br J Dermatol; 1998 Mar; 138(3):426-30. PubMed ID: 9580794
[TBL] [Abstract][Full Text] [Related]
10. Analysing the serum levels of tumour markers and primary tumour data in stage III melanoma patients in correlation to the extent of lymph node metastases--a prospective study in 231 patients.
Neuss H; Koplin G; Raue W; Reetz C; Mall JW
Acta Chir Belg; 2011; 111(4):214-8. PubMed ID: 21954736
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the Serum Tumor Markers S100 and Melanoma-inhibitory Activity (MIA) in the Monitoring of Patients with Metastatic Melanoma Receiving Vaccination Immunotherapy with Dendritic Cells.
Uslu U; Schliep S; Schliep K; Erdmann M; Koch HU; Parsch H; Rosenheinrich S; Anzengruber D; Bosserhoff AK; Schuler G; Schuler-Thurner B
Anticancer Res; 2017 Sep; 37(9):5033-5037. PubMed ID: 28870930
[TBL] [Abstract][Full Text] [Related]
12. [S100 protein as tumoral marker in melanoma patients. Comparative study with sentinel node biopsy and whole body FDG-PET].
Ortiz B; Vázquez C; Martínez C; Giménez J; Sanmartín O; de los Dolores V; Ortega F; Maíquez J; Fliquete MV
Rev Esp Med Nucl; 2003; 22(2):87-96. PubMed ID: 12646097
[TBL] [Abstract][Full Text] [Related]
13. Clinical value of protein S100 and melanoma-inhibitory activity (MIA) in malignant melanoma.
Tas F; Yasasever V; Duranyildiz D; Camlica H; Ustuner Z; Aydiner A; Topuz E
Am J Clin Oncol; 2004 Jun; 27(3):225-8. PubMed ID: 15170138
[TBL] [Abstract][Full Text] [Related]
14. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma.
Deichmann M; Benner A; Bock M; Jäckel A; Uhl K; Waldmann V; Näher H
J Clin Oncol; 1999 Jun; 17(6):1891-6. PubMed ID: 10561230
[TBL] [Abstract][Full Text] [Related]
15. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
[TBL] [Abstract][Full Text] [Related]
16. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma.
Abraha HD; Fuller LC; Du Vivier AW; Higgins EM; Sherwood RA
Br J Dermatol; 1997 Sep; 137(3):381-5. PubMed ID: 9349333
[TBL] [Abstract][Full Text] [Related]
17. Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma.
Bánfalvi T; Boldizsár M; Gergye M; Gilde K; Kremmer T; Ottó S
Pathol Oncol Res; 2002; 8(3):183-7. PubMed ID: 12515998
[TBL] [Abstract][Full Text] [Related]
18. Neuron-specific enolase as a prognostic factor in metastatic malignant melanoma.
Wibe E; Hannisdal E; Paus E; Aamdal S
Eur J Cancer; 1992; 28A(10):1692-5. PubMed ID: 1389487
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy.
Hauschild A; Engel G; Brenner W; Gläser R; Mönig H; Henze E; Christophers E
Br J Dermatol; 1999 Jun; 140(6):1065-71. PubMed ID: 10354072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
